Aneyefor News

(Albany, New York) – October 19, 2026 – The market dynamics for cytokine release syndrome (CRS) are expected to witness significant growth driven by the expanding use of chimeric antigen receptor (CAR) T-cell therapies, increasing adoption of bispecific antibodies, and rising demand for effective approaches to manage treatment-related inflammatory complications. Additionally, the development of emerging therapies such as CTO1681 by CytoAgents and other immunomodulatory approaches is expected to influence the market in the coming years.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Cytokine Release Syndrome Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of cytokine release syndrome, including historical and forecasted epidemiology, market trends, emerging therapies, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Key Takeaways from the Cytokine Release Syndrome Market

• The cytokine release syndrome market across the seven major markets (7MM) is projected to grow at a CAGR of approximately 22% from 2026 to 2036. The exact 2025 market size and projected 2036 market value are not publicly disclosed in the report summary.

• The United States accounted for the largest number of CRS incident cases among the 7MM in 2025, representing approximately 25% of total cases.

• Among the EU4 and the United Kingdom, Germany accounted for the highest incidence of CRS in 2025, followed by France, while Spain reported the lowest incidence.

• CRS is increasingly associated with CAR T-cell therapies and bispecific antibodies used to treat hematological malignancies.

• Tocilizumab (ACTEMRA), developed by Genentech, is an established treatment for CAR T-cell-induced severe or life-threatening CRS.

• Key companies in the CRS treatment landscape include CytoAgents and Genentech.

• Promising therapies and treatment approaches include CTO1681, an investigational immunomodulator developed by CytoAgents, and established IL-6 receptor inhibition with tocilizumab.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/cytokine-release-syndrome-market

Key Factors Driving the Cytokine Release Syndrome Market

Increasing Adoption of CAR T-Cell Therapies: The growing use of CAR T-cell therapies for hematological malignancies is a major factor influencing the CRS market. These treatments activate immune cells to recognize and attack cancer cells, but can also trigger excessive cytokine release. As CAR T-cell therapies become available to more patients and move into additional treatment settings, the need for effective CRS recognition and management is expected to increase.

Growing Use of Bispecific Antibodies: Bispecific antibodies are increasingly being used in oncology to direct immune cells against cancer cells. Although these therapies offer important treatment opportunities, they can cause CRS in some patients. Increasing use of these agents is contributing to demand for supportive care, monitoring, and targeted treatments that control inflammatory complications.

Established Role of Tocilizumab: Tocilizumab, an interleukin-6 (IL-6) receptor antagonist, is an established treatment for severe or life-threatening CRS associated with CAR T-cell therapy. By blocking IL-6 signaling, it helps control excessive inflammation. Its established clinical role and inclusion in treatment protocols make it a key component of the current CRS therapeutic landscape.

Advancements in Emerging Therapies: Research is exploring treatments that may prevent or reduce CRS while preserving the antitumor activity of immune-based cancer therapies. CTO1681, developed by CytoAgents, is an investigational oral immunomodulator designed to modulate inflammatory pathways associated with CRS. Its potential clinical role will depend on further safety and efficacy evidence.

Improved Diagnosis and Clinical Management: Earlier recognition of CRS and standardized severity grading can support timely intervention. Clinical assessment commonly considers fever, hypotension, and hypoxia, while distinguishing CRS from conditions such as sepsis and immune effector cell-associated neurotoxicity syndrome (ICANS). Better risk assessment and treatment protocols may help improve patient outcomes and healthcare resource utilization.

Cytokine Release Syndrome Competitive Landscape

Several companies are involved in developing or commercializing therapies relevant to the management of cytokine release syndrome. The competitive landscape includes established cytokine-targeted treatments and investigational approaches designed to regulate excessive immune activation.

Key companies and therapies include:

• Genentech: Tocilizumab (ACTEMRA), an IL-6 receptor antagonist used to manage severe or life-threatening CAR T-cell-induced CRS.

• CytoAgents: CTO1681, an investigational oral immunomodulator being studied for its potential to reduce inflammatory toxicity associated with CAR T-cell therapy.

Tocilizumab remains an important established therapy for CRS, while investigational approaches such as CTO1681 aim to address additional unmet needs, including the prevention or mitigation of inflammatory complications without compromising antitumor activity. The future competitive landscape will depend on clinical outcomes, regulatory decisions, safety, efficacy, and adoption within oncology treatment protocols.

Discover more about therapies set to influence the cytokine release syndrome market @ Cytokine Release Syndrome Treatment Landscape.

Recent Developments in the Cytokine Release Syndrome Market

• December 2025: CytoAgents announced that preliminary safety data from its Phase I/II clinical trial of CTO1681 would be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. The company reported that CTO1681 was well tolerated at the 10 μg three-times-daily dose.

• December 2025: CytoAgents announced that data relating to its investigational new drug (IND)-enabling research would be presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025. The reported research examined CTO1681’s effects on cytokines associated with CRS and its potential to preserve CAR T-cell-mediated tumor killing in preclinical studies.

• September 2024: CytoAgents announced that it had received a USD 2 million grant from the National Institutes of Health (NIH) to accelerate the development of CTO1681.

• August 2017: The US Food and Drug Administration (FDA) approved intravenous tocilizumab (ACTEMRA) for the treatment of CAR T-cell-induced severe or life-threatening CRS in patients aged two years and older.

What Is Cytokine Release Syndrome?

Cytokine release syndrome is an acute systemic inflammatory condition caused by the excessive release of cytokines from activated immune cells. It is commonly associated with immune-based cancer treatments, particularly CAR T-cell therapies and certain bispecific antibodies. CRS can range from mild symptoms, such as fever and fatigue, to severe complications involving hypotension, hypoxia, and multiple organ dysfunction.

Diagnosis is primarily clinical and relies on the timing of symptoms in relation to an immune effector therapy, the patient’s clinical presentation, and standardized severity grading systems. The American Society for Transplantation and Cellular Therapy (ASTCT) criteria classify CRS severity primarily according to fever, blood pressure changes, and oxygen requirements.

Treatment depends on the severity of the condition. Mild cases may require monitoring and supportive care, while more severe cases may require hospitalization, intravenous fluids, oxygen support, vasopressors, and targeted immunomodulation. Tocilizumab is an established treatment for severe or life-threatening CRS associated with CAR T-cell therapy, and corticosteroids may be used when clinically indicated.

Cytokine Release Syndrome Epidemiology Segmentation

The cytokine release syndrome epidemiology section provides insights into the historical and current patient burden, along with forecasted trends across the 7MM. DelveInsight’s report evaluates CRS epidemiology over the study period 2022–2036, segmented into:

• Total Incident Cases of Cytokine Release Syndrome

• Grade-specific Incident Cases of Cytokine Release Syndrome

• CRS Cases Associated with CAR T-Cell Therapies

• CRS Cases Associated with Bispecific Antibodies

• CRS Cases Associated with Allogeneic Transplantation

• Total Treated Cases of Cytokine Release Syndrome

According to DelveInsight’s analysis, the United States accounted for approximately 25% of total CRS incident cases across the 7MM in 2025. Germany reported the highest incidence among the EU4 and the United Kingdom, followed by France, while Spain reported the lowest incidence.

The incidence and severity of CRS vary according to the immunotherapy used, the underlying malignancy, patient characteristics, and treatment protocols. The report examines these factors to estimate the future patient burden and treatment requirements across the covered markets.

Scope of the Cytokine Release Syndrome Market Report

• Therapeutic Assessment: Current marketed therapies and emerging treatments for cytokine release syndrome.

• Market Dynamics: Key market drivers, barriers, forecast assumptions, and future market outlook.

• Key Companies: CytoAgents, Genentech, and other companies relevant to the CRS treatment landscape.

• Key Therapies: Tocilizumab (ACTEMRA) and CTO1681.

• Competitive Intelligence Analysis: Assessment of treatment mechanisms, clinical development, market competition, and potential opportunities.

• Unmet Needs and Market Access: Challenges in early diagnosis, severity prediction, treatment optimization, reimbursement, and management of therapy-associated inflammatory complications.

To know more about cytokine release syndrome companies working in the treatment market, visit @ Cytokine Release Syndrome Clinical Trials and Therapeutic Assessment.

Table of Contents

1. Cytokine Release Syndrome Market Report Introduction

2. Executive Summary for Cytokine Release Syndrome

3. SWOT Analysis of Cytokine Release Syndrome

4. Cytokine Release Syndrome Patient Share Overview at a Glance

5. Cytokine Release Syndrome Market Overview at a Glance

6. Cytokine Release Syndrome Background and Overview

7. Cytokine Release Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Cytokine Release Syndrome

9. Cytokine Release Syndrome Current Treatment and Medical Practices

10. Cytokine Release Syndrome Unmet Needs

11. Cytokine Release Syndrome Emerging Therapies

12. Cytokine Release Syndrome Market Outlook

13. Country-Wise Cytokine Release Syndrome Market Analysis (2022–2036)

14. Cytokine Release Syndrome Market Access and Reimbursement of Therapies

15. Cytokine Release Syndrome Market Drivers

16. Cytokine Release Syndrome Market Barriers

17. Cytokine Release Syndrome Appendix

18. Cytokine Release Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/